References
- WuDGaoYQiYChenLMaYLiYPeptide-based cancer therapy: opportunity and challengeCancer Lett20143511132224836189
- RedigAJMcAllisterSSBreast cancer as a systemic disease: a view of metastasisJ Intern Med2013274211312623844915
- NaginiSBreast cancer: current molecular therapeutic targets and new playersAnticancer Agents Med Chem2016172152163
- MineYMunirHNakanishiYSugiyamaDBiomimetic peptides for the treatment of cancerAnticancer Res20163673565357027354624
- CraikDJFairlieDPSpirosLDavidPThe future of peptide-based drugsChem Biol Drug Des201381113614723253135
- MarqusSPirogovaEPivaTJEvaluation of the use of therapeutic peptides for cancer treatmentJ Biomed Sci20172412128320393
- YangLYingCShenJAntitumor activity of SA12, a novel peptide, on SKBr-3 breast cancer cells via the mitochondrial apoptosis pathwayDrug Des Devel Ther2015913191330
- BertoliCSkotheimJMde BruinRAControl of cell cycle transcription during G1 and S phasesNat Rev Mol Cell Biol201314851852823877564
- EmmiPPeppiKKirsi-MariaHRistoBArjaJVThe prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancerBreast Cancer Res2013151R523336272
- ZugazagoitiaJGuedesCPonceSFerrerIMolina-PineloSPaz-AresLCurrent challenges in cancer treatmentClin Ther20163871551156627158009
- CiavarellaSMilanoADammaccoFSilvestrisFTargeted therapies in cancerBiodrugs2010242778820199123
- WickiARochlitzCTargeted therapies in breast cancerSwiss Med Weekly201214217w13550
- TripathyDTargeted therapies in breast cancerBreast J201511Suppl 1S30S35
- MeehanRRLewisJDBirdAPCharacterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNANucleic Acids Res19922019508550921408825
- HoKLMcNaeIWSchmiedebergLKloseRJBirdAPWalkinshawMDMeCP2 binding to DNA depends upon hydration at methyl-CpGMol Cell200829452553118313390
- NeupaneMClarkAPLandiniSMECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancyCancer Discov201661455826546296
- BernardDGilJDumontPThe methyl-CpG-binding protein MECP2 is required for prostate cancer cell growthOncogene20062591358136616331274
- TongDZhaoLHeKMECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effectOncotarget2016723348453485927166996
- ZhaoLLiuYTongDMeCP2 promotes gastric cancer progression through regulating FOXF1/Wnt5a/β-catenin and MYOD1/caspase-3 signaling pathwaysEBioMedicine2017168710028131747
- KochCSträtlingWHDNA binding of methyl-CpG-binding protein MeCP2 in human MCF7 cellsBiochemistry200443175011502115109260
- KotakeYNaemuraMMurasakiCInoueYOkamotoHTranscriptional regulation of the p16 tumor suppressor geneAnticancer Res20153584397440126168478
- WangLTangLXieRNieWChenLGuanXp16 promoter hyper-methylation is associated with increased breast cancer riskMol Med Rep20126490490822824969
- LiuTNiuYFengYMethylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breastHum Pathol200839111637164618657295
- HochhauserDSchniedersBErcikanabaliEEffect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell lineJ Natl Cancer Inst19968818126912758797766
- LiZCuiJYuQWuXPanALiLEvaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancersAm J Transl Res20168114215327069548
- Milde-LangoschKRiethdorfSRole of cell cycle regulatory proteins in gynecological cancerJ Cell Physiol2003196222424412811815
- SemczukAJakowickiJAAlterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesisCancer Lett2004203111214670612